Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 17 Carcinoma, Hepatocellular 8 Nasopharyngeal Carcinoma 7 Recurrence 6 Neoplasms 6 Esophageal Neoplasms 6 Breast Neoplasms 6 Stomach Neoplasms 5 Neoplasm Metastasis 5 Esophageal Squamous Cell Carcinoma 5 Colorectal Neoplasms 5 Locally Advanced Rectal Cancer 4 Carcinoma, Renal Cell 4 Urinary Bladder Neoplasms 3 Small Cell Lung Carcinoma 3 Sarcoma 3 Rectal Neoplasms 3 Melanoma 3 Head and Neck Neoplasms 3 Colonic Neoplasms 3 Cholangiocarcinoma 3 Uterine Cervical Neoplasms 2 Squamous Cell Carcinoma of Head and Neck 2 Solid Tumors 2 Lymphoma, Large B-Cell, Diffuse 2 Lymphoma, B-Cell 2 Leukemia, Myeloid, Acute 2 Hyperthermia 2 Chondrosarcoma 2 Carcinoma, Transitional Cell 2

Interventions

Etoposide 2 olaparib 1 ceralasertib 1 apatinib 1 anlotinib 1 Platinum 1 Paclitaxel 1 Immune Checkpoint Inhibitors 1 Carboplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × SCLC × Immune Checkpoint Inhibitors × Clear all

NCT07110103 2026-02-27

JACKPOT38

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2 Recruiting

SCLC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡